Free Trial
NASDAQ:BGMS

Cyclacel Pharmaceuticals (BGMS) Stock Price, News & Analysis

Cyclacel Pharmaceuticals logo
$1.00 -0.05 (-5.14%)
Closing price 05/15/2026 04:00 PM Eastern
Extended Trading
$1.01 +0.02 (+1.91%)
As of 05/15/2026 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Cyclacel Pharmaceuticals Stock (NASDAQ:BGMS)

Advanced

Key Stats

Today's Range
$1.00
$1.07
50-Day Range
$0.83
$1.19
52-Week Range
$0.73
$34.65
Volume
14,800 shs
Average Volume
68,712 shs
Market Capitalization
$5.50 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
Sell

Company Overview

Cyclacel Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
28th Percentile Overall Score

BGMS MarketRank™: 

Cyclacel Pharmaceuticals scored higher than 28% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Cyclacel Pharmaceuticals has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

  • Amount of Analyst Coverage

    Cyclacel Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

  • Read more about Cyclacel Pharmaceuticals' stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Cyclacel Pharmaceuticals is -0.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Cyclacel Pharmaceuticals is -0.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Cyclacel Pharmaceuticals has a P/B Ratio of 0.71. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    1.36% of the float of Cyclacel Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Cyclacel Pharmaceuticals has a short interest ratio ("days to cover") of 0.38, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Cyclacel Pharmaceuticals has recently decreased by 38.31%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Cyclacel Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Cyclacel Pharmaceuticals does not have a long track record of dividend growth.

  • News Sentiment

    Cyclacel Pharmaceuticals has a news sentiment score of 0.96. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Manufacturing companies.
  • News Coverage This Week

    MarketBeat has tracked 4 news articles for Cyclacel Pharmaceuticals this week, compared to 1 article on an average week.
  • Search Interest

    3 people have searched for BGMS on MarketBeat in the last 30 days.
  • MarketBeat Follows

    1 people have added Cyclacel Pharmaceuticals to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Cyclacel Pharmaceuticals insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    51.20% of the stock of Cyclacel Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    23.58% of the stock of Cyclacel Pharmaceuticals is held by institutions.

  • Read more about Cyclacel Pharmaceuticals' insider trading history.
Receive BGMS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cyclacel Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

BGMS Stock News Headlines

Bio Green Med Solution Inc
You're not getting into the SpaceX IPO. Do this instead.
The SpaceX IPO is expected to price at $1.75 trillion - and retail investors won't get an allocation. Banks and insiders have already locked it up. But there is one small, publicly traded company that builds the critical infrastructure SpaceX cannot operate without. Dylan Jovine is releasing the ticker name today at no cost.tc pixel
See More Headlines

BGMS Stock Analysis - Frequently Asked Questions

Cyclacel Pharmaceuticals' stock was trading at $1.48 at the start of the year. Since then, BGMS shares have decreased by 32.7% and is now trading at $0.9960.

Cyclacel Pharmaceuticals, Inc. (NASDAQ:BGMS) announced its quarterly earnings results on Friday, May, 15th. The company reported ($0.04) earnings per share (EPS) for the quarter.

Shares of BGMS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
5/15/2026
Today
5/16/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical Preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:BGMS
CIK
1130166
Web
N/A
Employees
14
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($4.50)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$3 million
Net Margins
N/A
Pretax Margin
-400.40%
Return on Equity
-58.15%
Return on Assets
-48.99%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
4.70
Quick Ratio
3.66

Sales & Book Value

Annual Sales
$750 thousand
Price / Sales
7.33
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.40 per share
Price / Book
0.71

Miscellaneous

Outstanding Shares
5,520,000
Free Float
2,693,000
Market Cap
$5.50 million
Optionable
N/A
Beta
-0.49
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply click the link below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

This page (NASDAQ:BGMS) was last updated on 5/16/2026 by MarketBeat.com Staff.
From Our Partners